NCT02753283 - Preventing Osteoporosis Using Denosumab | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions

Osteoporosis, PostmenopausalOsteoporosisOsteoporotic Fractures

Interventions

DRUG

denosumab

Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

DRUG

Placebo

Semi-annual saline injection

DIETARY_SUPPLEMENT

Calcium and Vitamin D

Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

Trial Locations (1)

UPMC Senior Communities, Pittsburgh

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

Susan L. Greenspan

OTHER